Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
50
RDY Quote, Financials, Valuation and Earnings
Last price:
$14.17
Seasonality move
:
-1.19%
Day range:
$14.08 - $14.20
52-week range:
$12.26 - $16.17
Dividend yield:
0.66%
P/E ratio:
17.34x
P/S ratio:
2.97x
P/B ratio:
2.92x
Volume:
969.4K
Avg. volume:
1.1M
1-year change:
-9.06%
Market cap:
$11.8B
Revenue:
$3.9B
EPS (TTM):
$0.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$983.7M | $0.19 | -2.63% | 3.83% | $14.58 |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
ESPR
Esperion Therapeutics, Inc.
|
$77.2M | -$0.08 | 138.3% | -48.14% | $6.50 |
|
HDB
HDFC Bank Ltd.
|
$4.9B | $0.36 | -60.81% | -3.82% | $43.93 |
|
NVO
Novo Nordisk A/S
|
$11.9B | $0.66 | -0.5% | 1.27% | $53.33 |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$14.16 | $14.58 | $11.8B | 17.34x | $0.09 | 0.66% | 2.97x |
|
CCM
Concord Medical Services Holdings Ltd.
|
$3.76 | -- | $16.3M | -- | $0.00 | 0% | 0.32x |
|
ESPR
Esperion Therapeutics, Inc.
|
$4.04 | $6.50 | $957.8M | -- | $0.00 | 0% | 2.63x |
|
HDB
HDFC Bank Ltd.
|
$36.46 | $43.93 | $186.6B | 18.14x | $0.38 | 1.03% | 2.49x |
|
NVO
Novo Nordisk A/S
|
$52.40 | $53.33 | $232.8B | 15.26x | $0.58 | 3.3% | 5.00x |
|
ZLAB
Zai Lab Ltd.
|
$18.33 | $49.17 | $2B | -- | $0.00 | 0% | 4.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
14.04% | -0.469 | 5.65% | 1.12x |
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -1.533 | 77.28% | 0.19x |
|
ESPR
Esperion Therapeutics, Inc.
|
408.15% | 2.653 | 109.82% | 0.65x |
|
HDB
HDFC Bank Ltd.
|
52.46% | -0.421 | 38.1% | 4.85x |
|
NVO
Novo Nordisk A/S
|
37.33% | 1.647 | 6.46% | 0.46x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$517.5M | $178.5M | 14.9% | 17.11% | 17.71% | $49.2M |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
ESPR
Esperion Therapeutics, Inc.
|
$46M | -$10M | -60.77% | -- | -11.41% | -$23.9M |
|
HDB
HDFC Bank Ltd.
|
-- | $3.1B | 6.38% | 14% | 61.91% | -- |
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Dr. Reddy's Laboratories Ltd. vs. Competitors
-
Which has Higher Returns RDY or CCM?
Concord Medical Services Holdings Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of --. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Concord Medical Services Holdings Ltd.'s return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B CCMConcord Medical Services Holdings Ltd.-- -- $727.8M -
What do Analysts Say About RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 3.3%. On the other hand Concord Medical Services Holdings Ltd. has an analysts' consensus of -- which suggests that it could grow by 219.15%. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 CCMConcord Medical Services Holdings Ltd.0 0 0 -
Is RDY or CCM More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Concord Medical Services Holdings Ltd. has a beta of -1.164, suggesting its less volatile than the S&P 500 by 216.414%.
-
Which is a Better Dividend Stock RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Concord Medical Services Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Concord Medical Services Holdings Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or CCM?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Concord Medical Services Holdings Ltd. quarterly revenues of --. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Concord Medical Services Holdings Ltd.'s net income of --. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.34x while Concord Medical Services Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 0.32x for Concord Medical Services Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 17.34x $1B $163.4M CCMConcord Medical Services Holdings Ltd.0.32x -- -- --
-
Which has Higher Returns RDY or ESPR?
Esperion Therapeutics, Inc. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -35.89%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Esperion Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M -
What do Analysts Say About RDY or ESPR?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 3.3%. On the other hand Esperion Therapeutics, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 60.95%. Given that Esperion Therapeutics, Inc. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Esperion Therapeutics, Inc. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ESPREsperion Therapeutics, Inc.3 1 0 -
Is RDY or ESPR More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Esperion Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.85%.
-
Which is a Better Dividend Stock RDY or ESPR?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Esperion Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Esperion Therapeutics, Inc. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ESPR?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Esperion Therapeutics, Inc. quarterly revenues of $87.3M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Esperion Therapeutics, Inc.'s net income of -$31.3M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.34x while Esperion Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 2.63x for Esperion Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 17.34x $1B $163.4M ESPREsperion Therapeutics, Inc.2.63x -- $87.3M -$31.3M
-
Which has Higher Returns RDY or HDB?
HDFC Bank Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 17.18%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat HDFC Bank Ltd.'s return on equity of 14%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B HDBHDFC Bank Ltd.-- $0.44 $131.1B -
What do Analysts Say About RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 3.3%. On the other hand HDFC Bank Ltd. has an analysts' consensus of $43.93 which suggests that it could grow by 20.48%. Given that HDFC Bank Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe HDFC Bank Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 HDBHDFC Bank Ltd.3 0 0 -
Is RDY or HDB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison HDFC Bank Ltd. has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.34%.
-
Which is a Better Dividend Stock RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. HDFC Bank Ltd. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.38 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. HDFC Bank Ltd. pays out 19.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or HDB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than HDFC Bank Ltd. quarterly revenues of $13.6B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than HDFC Bank Ltd.'s net income of $2.3B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.34x while HDFC Bank Ltd.'s PE ratio is 18.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 2.49x for HDFC Bank Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 17.34x $1B $163.4M HDBHDFC Bank Ltd.2.49x 18.14x $13.6B $2.3B
-
Which has Higher Returns RDY or NVO?
Novo Nordisk A/S has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 26.68%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Novo Nordisk A/S's return on equity of 68.76%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B NVONovo Nordisk A/S76.12% $0.70 $42.7B -
What do Analysts Say About RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 3.3%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 2.13%. Given that Dr. Reddy's Laboratories Ltd. has higher upside potential than Novo Nordisk A/S, analysts believe Dr. Reddy's Laboratories Ltd. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 NVONovo Nordisk A/S5 4 2 -
Is RDY or NVO More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.
-
Which is a Better Dividend Stock RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Novo Nordisk A/S offers a yield of 3.3% to investors and pays a quarterly dividend of $0.58 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or NVO?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.34x while Novo Nordisk A/S's PE ratio is 15.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 5.00x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 17.34x $1B $163.4M NVONovo Nordisk A/S5.00x 15.26x $11.7B $3.1B
-
Which has Higher Returns RDY or ZLAB?
Zai Lab Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -30.98%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 3.3%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 168.25%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ZLABZai Lab Ltd.8 1 0 -
Is RDY or ZLAB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.34x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 4.45x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 17.34x $1B $163.4M ZLABZai Lab Ltd.4.45x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
